Loading clinical trials...
Loading clinical trials...
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Local Institution - 0077
Birmingham, Alabama, United States
Local Institution - 0030
El Cajon, California, United States
Local Institution - 0049
Torrance, California, United States
Local Institution - 0074
New Haven, Connecticut, United States
Local Institution - 0115
Aventura, Florida, United States
Local Institution - 0044
Brandon, Florida, United States
Local Institution - 0140
Gainesville, Florida, United States
Local Institution - 0133
Orlando, Florida, United States
Local Institution - 0032
Ormond Beach, Florida, United States
Local Institution - 0048
Tampa, Florida, United States
Start Date
March 26, 2019
Primary Completion Date
March 21, 2025
Completion Date
March 21, 2025
Last Updated
March 20, 2026
261
ACTUAL participants
BMS-986165
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT06647069
NCT07371468
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06333483